IP Library Granted Patent US 8,278,271
Granted Patent B2
US 8,278,271 · App. 12/001,258 · Granted Oct 2, 2012

Inhibiting collagen-induced platelet aggregation and activation with peptide variants

Assignee: University of Massachusetts
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,271
App. No.
12/001,258
Granted
Oct 2, 2012
Kind
B2
Abstract

The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcRγ signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The present invention further relates to the therapy of various disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition involving platelet activation and aggregation, and more particularly, collagen-induced platelet activation and aggregation. They also are useful in the production of medical devices comprising peptide matrices (i.e., for example, cardiovascular stents).

Claims (2)

1. A peptide comprising an amino acid sequence consisting of G-N-L-V-R-I-X 1 -X 2 -X 3 -A-X 4 -X 5 -X 6 -X 7 -I (SEQ ID NO:1), wherein X 1 is selected from the group consisting of C, L or G; X 2 is selected from the group consisting of L or A; X 3 is selected from the group consisting of G or R; X 4 is selected from the group consisting of V or I; X 5 is selected from the group consisting of I, L or R; X 6 is selected from the group consisting of I or L; and X 7 is selected from the group consisting of I or L and further comprising an N-terminal sugar conjugate and a C-terminal lipid conjugate wherein said sugar conjugate is 1-amino-glucose succinate and said lipid conjugate is selected from the group consisting of Gly-Tris-monopalmitate, Gly-Tris-dipalmitate, Gly-Tris-tripalmitate, 2-aminododecanoate, and myristoylate conjugates.

2. The peptide of claim 1 , wherein said amino acid sequence further comprises at least one amino acid selected from the group consisting of an L-amino acid and a D-amino acid.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 12, 2013
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031804/0288 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2008
From: SIGALOV, ALEXANDER B.
To: MASSACHUSETTS MEDICAL SCHOOL, UNIVERSITY OF
Reel/Frame 021183/0598 →
Continuity (2)
Provisional Application 60874694 · Dec 13, 2006
Related Publication 20090075899A1 · Mar 19, 2009